ArticleAnnals of the American Thoracic Society2015
Association of plasma adipokines with chronic obstructive pulmonary disease severity and progression.
Article in Annals of the American Thoracic Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients.PloS one · 2019Trial
- Identifying Metabolomic Biomarkers of Lung Function Decline in People with HIV.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Longitudinal analysis of adiponectin to leptin and apolipoprotein B to A1 ratios as markers of future airflow obstruction and lung function decline.Scientific reports · 2024Observational
- Dynamic and prognostic proteomic associations with FEVmedRxiv : the preprint server for health sciences · 2024Article
- Visualization of the relationship between metabolism and lung diseases from the perspective of bibliometric analysis: research trends and future prospects.Frontiers in medicine · 2024Article
- Biomarker-based clustering of patients with chronic obstructive pulmonary disease.ERJ open research · 2023Article
- Body Composition and COPD: A New Perspective.International journal of chronic obstructive pulmonary disease · 2023Review
- Clustering-based COPD subtypes have distinct longitudinal outcomes and multi-omics biomarkers.BMJ open respiratory research · 2022Observational
- Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors.Experimental gerontology · 2021Review
- Characteristics of chronic obstructive pulmonary disease patients with robust progression of emphysematous change.Scientific reports · 2021Observational
- Serum Concentration of the Phytohormone Abscisic Acid Is Associated With Immune-Regulatory Mediators and Is a Potential Biomarker of Disease Severity in Chronic Obstructive Pulmonary Disease.Frontiers in medicine · 2021Article
- Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview.Metabolites · 2020Review
- Identification of Critical Windows of Metabolic Programming of Metabolism and Lung Function in Male Offspring of Obese Dams.Clinical and translational science · 2020Article
- Should patients with obesity be more afraid of COVID-19?Obesity reviews : an official journal of the International Association for the Study of Obesity · 2020Review
- Chronic Obstructive Pulmonary Disease in Women: A Biologically Focused Review with a Systematic Search Strategy.International journal of chronic obstructive pulmonary disease · 2020Review
- Molecular Characteristics and Treatment of Endothelial Dysfunction in Patients with COPD: A Review Article.International journal of molecular sciences · 2019Review
- An immunometabolic pathomechanism for chronic obstructive pulmonary disease.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Metabolic reprogramming in the pathogenesis of chronic lung diseases, including BPD, COPD, and pulmonary fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2018Review
- Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort.Respiratory research · 2018Article
- Plasma Leptin and Reduced FEVPM & R : the journal of injury, function, and rehabilitation · 2018Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleTwo adipokines, leptin and adiponectin, regulate metabolic and inflammatory systems reciprocally. The role of adiponectin in chronic obstructive pulmonary disease (COPD) has been studied. However, there are few data evaluating the relationship of plasma leptin with COPD severity or progression.
objectivesThe objective of this study was to evaluate the relationship of leptin, adiponectin, and the leptin/adiponectin ratio with COPD severity and progression according to COPD phenotypes.
methodsPlasma leptin and adiponectin levels were measured in 196 subjects with COPD selected from the Korean Obstructive Lung Disease cohort. Using a linear regression model and mixed linear regression, we determined the relationship of plasma leptin and adiponectin levels and the leptin/adiponectin ratio to COPD severity and progression over 3 years. MEASUREMENTS AND MAIN
resultsThe concentration of adiponectin in plasma positively correlated with percent emphysema on initial computed tomography (CT) (adjusted P = 0.022), whereas plasma leptin concentrations and the leptin/adiponectin ratio exhibited a significant inverse correlation with initial FEV1 (adjusted P = 0.013 for leptin and adjusted P = 0.041 for leptin/adiponectin ratio). Increased plasma leptin and leptin/adiponectin ratio were significantly associated with change in percent emphysema over 3 years (adjusted P = 0.037 for leptin and adjusted P = 0.029 for leptin/adiponectin ratio), whereas none of the adipokines demonstrated an association with FEV1 decline over the 3-year period.
conclusionsPlasma adiponectin and leptin vary according to COPD phenotypes. Plasma leptin and the leptin/adiponectin ratio, but not adiponectin, were significantly associated with changes in CT-assessed emphysema, suggesting a potential role as a biomarker in emphysema progression in patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.